Zhe Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhe Zhao has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Yan Chen
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
2 shared publicationsErli Gao
Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
1 shared publication- Guangli Suo
CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Jiangsu, China.
1 shared publication Guoqin Jiang
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication- Hanfei Wu
School of Nano‐Tech and Nano‐Bionics University of Science and Technology of China Hefei Anhui China
1 shared publication - Hao Zhou
Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
1 shared publication
Latest Publications
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
- 13 May 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (6) , 1328-1342
High-throughput generation of patient-derived cancer stem cells for precision medicine using a microwell-chip platform
Substantial evidence indicates that cancer stem cells (CSCs) drive breast cancer (BRC) initiation, progression, therapy resistance, recurrence and metastasis. Evaluating drug efficacy against patient-derived CSCs can advance precision oncology. However, high-throughput isolation of functional CSCs from small clinical samples remains challenging. Tumoursphere formation, arising from the clonal expansion of a single cancer cell, is a standard in vitro method for CSC assay and enrichment. Here we show a microwell cell-chip culture platform that enables rapid, high-throughput generation of uniform micro-tumourspheres (MTSs) from limited BRC specimens, such as puncture biopsies, facilitating functional CSC enrichment and personalized drug testing within 8 days. Single-cell transcriptomics and limiting dilution tumour initiation assay confirm that MTSs recapitulate CSC functionality, uniformity and heterogeneity. MTSs predicted clinical outcomes in 16 patients with BRC with ~93.8% accuracy, underscoring their translational potential for personalized drug testing. Overall, this platform provides a robust tool for CSC-targeted precision medicine.
- Open Access
SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation
- 27 September 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115833
Lycorine inhibits pancreatic cancer cell growth and neovascularization by inducing Notch1 degradation and downregulating key vasculogenic genes
- 27 September 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 217, 115833
Lycorine inhibits pancreatic cancer cell growth and neovascularization by inducing Notch1 degradation and downregulating key vasculogenic genes